Legal Representation
Attorney
Ann Lamport Hammitte
USPTO Deadlines
Application History
37 events| Date | Code | Type | Description |
|---|---|---|---|
| Dec 23, 2019 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
| Dec 23, 2019 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED |
| May 29, 2019 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED |
| May 28, 2019 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| May 28, 2019 | EX5G | S | SOU EXTENSION 5 GRANTED |
| May 22, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| May 22, 2019 | EXT5 | S | SOU EXTENSION 5 FILED |
| Nov 23, 2018 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED |
| Nov 21, 2018 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Nov 21, 2018 | EXT4 | S | SOU EXTENSION 4 FILED |
| Nov 21, 2018 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Apr 3, 2018 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED |
| Mar 30, 2018 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Mar 30, 2018 | EXT3 | S | SOU EXTENSION 3 FILED |
| Mar 30, 2018 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Nov 21, 2017 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED |
| Nov 17, 2017 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Nov 17, 2017 | EXT2 | S | SOU EXTENSION 2 FILED |
| Nov 17, 2017 | EX2G | S | SOU EXTENSION 2 GRANTED |
| May 23, 2017 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED |
| May 19, 2017 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| May 19, 2017 | EXT1 | S | SOU EXTENSION 1 FILED |
| May 19, 2017 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Nov 22, 2016 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT |
| Sep 27, 2016 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Sep 7, 2016 | NPUB | O | NOTICE OF PUBLICATION |
| Aug 19, 2016 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Aug 6, 2016 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Aug 5, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Aug 5, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Aug 1, 2016 | ALIE | A | ASSIGNED TO LIE |
| Jul 26, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jan 27, 2016 | CNRT | F | NON-FINAL ACTION MAILED |
| Jan 23, 2016 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jan 22, 2016 | DOCK | D | ASSIGNED TO EXAMINER |
| Oct 8, 2015 | NWAP | I | NEW APPLICATION ENTERED |
| Oct 8, 2015 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Detailed Classifications
Class 005
pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
BIS RNAI; BIS RNA INTERFERENCE; BIS RIBONUCLEIC ACID INTERFERENCE
Classification
International Classes
005